Vivos Therapeutics Future Growth
Future criteria checks 2/6
Vivos Therapeutics is forecast to grow earnings and revenue by 34.5% and 22.9% per annum respectively while EPS is expected to grow by 76.2% per annum.
Key information
34.5%
Earnings growth rate
76.2%
EPS growth rate
| Healthcare earnings growth | 20.7% |
| Revenue growth rate | 22.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 19 Nov 2024 |
Recent future growth updates
Recent updates
Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely
Nov 12
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story
Sep 10It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks
Apr 25It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks
Feb 02Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)
Apr 18Vivos Therapeutics again delays Q2 2022 results
Aug 23Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada
Jun 29Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be
May 21Vivos Therapeutics: First Take After The Broad Market Sell-Off
Mar 06Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 19 | -8 | N/A | -8 | 2 |
| 12/31/2024 | 15 | -11 | N/A | -12 | 2 |
| 9/30/2024 | 15 | -13 | -13 | -12 | N/A |
| 6/30/2024 | 14 | -12 | -12 | -11 | N/A |
| 3/31/2024 | 13 | -16 | -12 | -11 | N/A |
| 12/31/2023 | 14 | -14 | -13 | -12 | N/A |
| 9/30/2023 | 15 | -15 | -13 | -12 | N/A |
| 6/30/2023 | 15 | -19 | -16 | -15 | N/A |
| 3/31/2023 | 16 | -20 | -18 | -17 | N/A |
| 12/31/2022 | 16 | -24 | -21 | -20 | N/A |
| 9/30/2022 | 16 | -25 | -22 | -21 | N/A |
| 6/30/2022 | 17 | -25 | -20 | -19 | N/A |
| 3/31/2022 | 17 | -22 | -20 | -18 | N/A |
| 12/31/2021 | 17 | -20 | -18 | -16 | N/A |
| 9/30/2021 | 16 | -24 | -17 | -15 | N/A |
| 6/30/2021 | 15 | -21 | -14 | -12 | N/A |
| 3/31/2021 | 13 | -19 | -9 | -9 | N/A |
| 12/31/2020 | 13 | -18 | -6 | -6 | N/A |
| 9/30/2020 | 13 | -9 | -4 | -4 | N/A |
| 6/30/2020 | 13 | -11 | -4 | -4 | N/A |
| 3/31/2020 | 12 | -12 | -4 | -4 | N/A |
| 12/31/2019 | 11 | -12 | -6 | -5 | N/A |
| 12/31/2018 | 4 | -9 | -7 | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VVOS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VVOS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VVOS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VVOS's revenue (22.9% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: VVOS's revenue (22.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VVOS's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 05:37 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vivos Therapeutics, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Edward Woo | Ascendiant Capital Markets LLC |
| Lucas Ward | Ascendiant Capital Markets LLC |